Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG's RNA platform technologies make the development of life science tools and diagnostics more effective and cost-efficient, enabling researchers to interrogate the entire transcriptome with smaller sample requirements and higher success rates.
April 14-19, 2023 | Join us at the AACR Annual Meeting in Orlando, FL
TUCSON, Ariz. , Jan. 09, 2023 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today provided an update on the progress of…
Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz. , Jan. 06, 2023 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its…
TUCSON, Ariz. , Dec. 28, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, provides here a summary of its second HTG…
Find product information, specifications and gene lists here.
Log in to your account to view technical manuals, package inserts, and other information related to your HTG EdgeSeq system or panels.
Log in to your accountPage last updated October 20, 2022
HTG is focused on delivering exceptional molecular profiling products and services. Contact us to find out how our unique technology can benefit you.